Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

efficacy of CLS001 in up to 240 subjects with papulopustular rosacea. The primary efficacy endpoint is the mean percent reduction in the number of inflammatory lesions. This study is expected to be completed by the end of 2007.

MX-2401 (IV lipopeptide; treatment of gram-positive bacterial infections): Good Laboratory Practices ("GLP") non-clinical studies were initiated in April 2007. Timing for completion of the GLP studies is dependent upon (1) additional manufacturing process development work; (2) initiation of the remaining required GLP studies; and (3) financial resources. Prior to initiating clinical trials in humans with MX-2401 the Company will need to complete the GLP studies, manufacture clinical trial GMP quality MX-2401, submit and obtain regulatory approval for initiating clinical studies, and various other activities. A $9.3 million investment commitment from Technology Partnerships Canada is associated with this program.

MX-4565 (small molecule; treatment of neurodegenerative diseases): In June 2007 we were awarded a grant from the Michael J. Fox Foundation to fund research in our MX-4565 program. The grant award agreement provides Elan Pharmaceuticals with a limited right to license the technology arising from the project for certain uses in the field of human disease.

Annual General Meeting: The Company hosted its 2007 Annual General Meeting yesterday. Re-elected to the board of directors were: David Scott (Chairman), Michael Abrams, Jim DeMesa, Richard DeVries, Alistair Duncan, Steve Gillis, Colin Mallet, Walter Moos, and Keith Schilit.

Other Matters: Further to the notice of early termination of our Vancouver facility lease due to a redevelopment of the site the Company has entered into an offer to lease approximately 5,000 square feet of space (currently office space, no labs) in close proximity to the existing facility and has made an offer to lease approximately 6,000 to 9,000 square feet of lab space in the Vancouver a
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... interface is the device," Nobel laureate Herbert Kroemer ... be found at the junctures where layers of ... nanotechnology, the interfaces between layers of metal oxides ... high-tech favorites as spintronics, high-temperature superconductors, ferroelectrics and ...
(Date:1/15/2014)... January 15, 2014 The Pittcon Organizing Committee ... Food Safety Tech , an e-Journal and producer of ... agreement for the second year for the co-location of Food ... The partnership provides that the registration fee to attend the ...
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
Breaking Biology Technology:A deeper look at interfaces 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3
... SAN FRANCISCO, July 20 Burrill & Company, a San ... Private Equity, Merchant Banking and Media, is pleased to announce that ... Director, for both Burrill & Company and Burrill Latin America. ... of Rio Bravo Venture Partners, an asset management firm created from ...
... BOZEN, Italy, July 20 Health ... with Charite-Universitatsmedizin,Berlin. Charite will install an i.v.STATION robot at ... The primary challenges in today,s ... time, waste, regulatory issues,lack of audit trails, motion injuries, ...
... , BASKING RIDGE, N.J., July ... the development of antithrombotic therapeutic aptamers with active control agents, ... Three new members (Dr. John Eikelboom of Canada, Dr. ... join the original members bringing the current size of the ...
Cached Biology Technology:Joao Paulo Baptista Joins Burrill & Company 2Health Robotics to Launch Germany's Installations of i.v.STATION(TM) at Charite-Universitatsmedizin Berlin 2Health Robotics to Launch Germany's Installations of i.v.STATION(TM) at Charite-Universitatsmedizin Berlin 3Regado Biosciences Expands Medical Advisory Board 2Regado Biosciences Expands Medical Advisory Board 3Regado Biosciences Expands Medical Advisory Board 4
(Date:4/24/2014)... 2014GEN Publishing recently introduced Clinical OMICs ... the application of OMICs technologies in clinical settings. ... beginning to transform medical care just as they ... decade-and-a-half. , "GEN,s editors and reporters have written ... transcriptomics, etc. etc. for years," said John Sterling, ...
(Date:4/24/2014)... invented a simple and cheap way of making a ... a high-resolution microscope. , Costing less than a cent, ... in developing countries and remote areas. , The lens ... The Australian National University (ANU) Research School of Engineering, ... Institute of Medical Research to find ways to transform ...
(Date:4/24/2014)... North Carolina State University and the University of North ... device that could help identify arterial plaque that is ... attack or stroke. , At issue is the plaque ... types of plaque are deemed "vulnerable," meaning that they ... and cause heart attack or stroke. , "Existing state-of-the-art ...
Breaking Biology News(10 mins):Droplet lens 2New ultrasound device may add in detecting risk for heart attack, stroke 2
... Assistant Professor, Department of Microbiology & Immunology, University of ... with one of two 2012 Merck Irving S. Sigal ... scientists to recognize and award excellence in basic research ... memory of Irving S. Sigal, an instrumental figure in ...
... Kaye Wachsmuth, Ph.D., International Public Health Consultant, DeLand, ... Public Health Award. This award, established in honor ... who has exhibited exemplary leadership and service in ... award "for almost forty years of implementing state-of-the-art ...
... Talk about throwing yourself into a relationship too soon. A ... gets a whiff of female sex attractant, he,s quicker to start ... prematurely when he,s still too cool for powerful flight. So his ... race. The study illustrates the tradeoff between being quick to ...
Cached Biology News:The American Society for Microbiology honors Susan Sharp 2The American Society for Microbiology honors I. Kaye Wachsmuth 2The American Society for Microbiology honors I. Kaye Wachsmuth 3Virgin male moths think they're hot when they're not 2Virgin male moths think they're hot when they're not 3Virgin male moths think they're hot when they're not 4Virgin male moths think they're hot when they're not 5
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
... in vitro diagnostic assays, all EIA/RIA plates ... uniform binding, high optical clarity and low ... part of the Certified Surface Chemistry Programme, ... within QA release specifications. Linkage: This CLS ...
... Stabilizer is an aqueous solution that contains ... stabilizing chemicals in a saline solution, pH ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane as ... a diluent and stabilizer for biologically active ...
AC input: 230 V...
Biology Products: